New drug combo aims to control advanced kidney cancer

NCT ID NCT05468697

Ongoing Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tests a new drug combination (belzutifan plus palbociclib) against belzutifan alone in people with advanced clear-cell kidney cancer that has worsened after at least two prior treatments. The main goals are to check safety and find the best dose of palbociclib when used with belzutifan. About 60 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 1001)

Boston, Massachusetts, 02215, United States
Emek Medical Center-oncology ( Site 3003)

Afula, 1834111, Israel
Frankston Hospital-Oncology and Haematology ( Site 2005)

Frankston, Victoria, 3199, Australia
Georgetown University Medical Center ( Site 1002)

Washington D.C., District of Columbia, 20007, United States
Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 1004)

Salt Lake City, Utah, 84112, United States
Macquarie University-MQ Health Clinical Trials Unit ( Site 2001)

Macquarie University, New South Wales, 2109, Australia
One Clinical Research ( Site 2008)

Nedlands, Western Australia, 6009, Australia
Rabin Medical Center-Oncology ( Site 3004)

Petah Tikva, 4941492, Israel
Rambam Health Care Campus-Oncology ( Site 3000)

Haifa, 3109601, Israel
Shaare Zedek Medical Center-Oncology ( Site 3002)

Jerusalem, 9103102, Israel
Sourasky Medical Center ( Site 3005)

Tel Aviv, 6423906, Israel
University of Chicago Medical Center ( Site 1007)

Chicago, Illinois, 60637, United States
Westmead Hospital ( Site 2006)

Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.